BIAF (bioAffinity) Gross Margin

bioAffinity Technologies (BIAF) is accelerating its time-to-market through partnerships with tumor screening laboratories. This gross profit margin chart demonstrates the financial efficiency of this strategy, where 20.40 determines the current level of this parameter. Its status as a scientific leader in non-invasive diagnostics confirms the brand's authority, while the modernization of production facilities ensures a stable output of tests.
Analytical breakdowns and data insights for company bioAffinity Technologies (BIAF)

To find a fundamental floor, it is essential for investors to evaluate the efficiency of direct production. At bioAffinity Technologies (BIAF), the high value of CyPath Lung patents and stringent FDA oversight create significant added value for every service. An analysis of gross margin on GURU.Markets reveals the portion of revenue remaining after cost of goods sold, confirming the asset's ability to generate profit and maintain stability without excessive borrowing.